Skip to main content

Systemic Diseases

The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.

Publications

Are Circulating FGF21 and NT-proBNP promising novel biomarkers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome?

PMID: 33353469
Journal: ANTIOXIDANTS & REDOX SIGNALING
Year: 2021
Reference: Antioxid Redox Signal. 2021 Jun 20;34(18):1420-1427. doi: 10.1089/ars.2020.8230. Epub 2021 Feb 11.
Impact factor: 8.401
Publication type: Paper in international publication
Authors: Castro-Marrero, Jesus, Domingo, Joan Carles, Cordobilla, Begona, Ferrer, Roser, Giralt, Marina, Alegre-Martin, Jose et al.
DOI: 10.1089/ars.2020.8230

Heart Disease in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: a screening approach proposal.

PMID: 33493294
Journal: RHEUMATOLOGY
Year: 2021
Reference: Rheumatology (Oxford). 2021 Oct 2;60(10):4538-4547. doi: 10.1093/rheumatology/keab027.
Impact factor: 7.58
Publication type: Paper in international publication
Authors: Garcia-Vives, Eloi, Rodriguez-Palomares, J F, Harty, Len, Solans-Laque, Roser, Jayne, David et al.
DOI: 10.1093/rheumatology/keab027

Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns.

PMID: 33020895
Journal: CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Year: 2021
Reference: Clin Exp Immunol. 2021 Feb;203(2):209-218. doi: 10.1111/cei.13530. Epub 2020 Nov 2.
Impact factor: 4.33
Publication type: Paper in international publication
Authors: Oristrell, Joaquim, Loureiro-Amigo, Jose, Solans, Roser, Valenzuela, Ma Pau, Monsalvez, Victor, Segarra, Alfons, Amengual, Ma Jose, Marin, Ana, Feijoo, Carlos, Tolosa, Carles et al.
DOI: 10.1111/cei.13530

Omalizumab for the treatment of Chronic Inducible Urticaria in 80 patients.

PMID: 32730636
Journal: BRITISH JOURNAL OF DERMATOLOGY
Year: 2021
Reference: Br J Dermatol. 2021 Jan;184(1):167-168. doi: 10.1111/bjd.19425. Epub 2020 Sep 2.
Impact factor: 9.302
Publication type: Letter or abstract
Authors: Gimenez-Arnau, A, Fernandez Chico, N, Guilabert Vidal, A, Sala Cunill, A, Exposito-Serrano, V, Curto Barredo, L, Aguilera Peiro, P, Gomez Armayones, S, Serra-Baldrich, E, Spertino, J et al.
DOI: 10.1111/bjd.19425

Anti-il6-r tocilizumab in refractory and non-infectious uveitic cystoid macular edema. Multicenter study of 25 patients.

PMID: 30660771
Journal: AMERICAN JOURNAL OF OPHTHALMOLOGY
Year: 2019
Reference: Am J Ophthalmol. 2019 Apr;200:85-94. doi: 10.1016/j.ajo.2018.12.019. Epub 2019 Jan 17.
Impact factor: 4.483
Publication type: Paper in international publication
Authors: Modesto, Consuelo, Gonzalez-Vela, Carmen, Pablo-Demetrio, Rosalia, Aurrecoechea, Elena, Cordero, Miguel, Dominguez-Casas, Lucia C, Atienza-Mateo, Belen, Martin-Varillas, Jose Luis, Loricera, Javier, Palmou-Fontana, Natalia et al.
DOI: 10.1016/j.ajo.2018.12.019

Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.

PMID: 30655091
Journal: SEMINARS IN ARTHRITIS AND RHEUMATISM
Year: 2019
Reference: Semin Arthritis Rheum. 2019 Aug;49(1):126-135. doi: 10.1016/j.semarthrit.2019.01.003. Epub 2019 Jan 5.
Impact factor: 5.072
Publication type: Paper in international publication
Authors: Loricera, Javier, Aldasoro, Vicente, Castaneda, Santos, Villa, Ignacio, Humbria, Alicia, Moriano, Clara, Romero-Yuste, Susana, Narvaez, Javier, Gomez-Arango, Catalina, Perez-Pampin, Eva et al.
DOI: 10.1016/j.semarthrit.2019.01.003

Efficacy and safety of omalizumab (Xolair(R)) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial.

PMID: 30654196
Journal: Journal of Allergy and Clinical Immunology-In Practice
Year: 2019
Reference: J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1599-1609.e1. doi: 10.1016/j.jaip.2018.12.025. Epub 2019 Jan 15.
Impact factor: 7.55
Publication type: Paper in international publication
Authors: Nunez-Cordoba, Jorge M, Baeza, Maria Luisa, Echechipia, Susana, Gaig, Pere, Garcia, Blanca Esther, Labrador-Horrillo, Moises, Sala-Cunill, Ana, Bresco, Marina Sabate, Beristain, Ana, Quinones, Dolores et al.
DOI: 10.1016/j.jaip.2018.12.025

Unexpected Relevant Role of Gene Mosaicism in Primary Immunodeficiency Diseases.

PMID: 30273710
Journal: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Year: 2019
Reference: J Allergy Clin Immunol. 2019 Jan;143(1):359-368. doi: 10.1016/j.jaci.2018.09.009. Epub 2018 Sep 29.
Impact factor: 14.11
Publication type: Paper in international publication
Authors: Balderrama-Rodriguez, Angelica, Ramos, Eduardo, Modesto, Consuelo, Mesa-Del-Castillo, Pablo, Ortego-Centeno, Norberto, Clemente, Daniel, Souto, Alejandro, Palmou, Natalia, Remesal, Agustin, Leslie, Kieron S et al.
DOI: 10.1016/j.jaci.2018.09.009

Blog

News

Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.

It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.

The study showing how thrombocytopenia increases the risk of thrombosis in patients with antiphospholipid syndrome has been considered the best paper published in 2021.